Fraudster Elizabeth Holmes’ partner launches startup in same field where she failed: ‘not Theranos 2.0’

Theranos fraudster Elizabeth Holmes partner Billy Evans has launched a startup in the same field blood testing where Holmes failed and ended up in prison The company is called Haemanthus the name of a plant called a blood lily and on Sunday it denied that Holmes was involved Yes our CEO Billy Evans is Elizabeth Holmes partner Haemanthus revealed on social media platform X Skepticism is rational Elizabeth Holmes has zero involvement in Haemanthus This is not Theranos Haemanthus reported would use a system called Raman spectroscopy using lasers and other light beams and artificial intelligence to analyze samples We re starting with veterinary medicine the company noted on X It s practical and meaningful It validates our hardware helps animals who can t describe effects and builds the foundation for human applications Holmes has two children with Evans a hotel heir with a bachelor s degree in economics from the Massachusetts Institute of Tool Evans was a fixture at the federal courthouse in San Jose during Holmes four-month trial for felony fraud Holmes is serving a federal prison sentence for bilking investors in her now-defunct Palo Alto-based Theranos out of hundreds of millions of dollars Jurors in her trial heard she made false alleges about the company s blood-testing machines which were touted to conduct a full range of tests using just a sparse drops of blood from a fingerprick but in reality could perform only a handful Related Articles Elizabeth Holmes jury consultant aiding Diddy s million defense gang Theranos felon Elizabeth Holmes loses again in court options for early freedom narrow Elizabeth Holmes keeps fighting proposes appeal judges were confused and mistaken A line that can t be crossed Elizabeth Holmes prosecutor on her fraud affair and lessons for Silicon Valley Theranos fraudster Elizabeth Holmes loses her appeal Haemanthus claimed its tool using lasers and other light beams to analyze samples according to a patent follows a different paradigm from that of Holmes failed startup Theranos attempted to miniaturize existing tests the company explained Our approach is fundamentally different We use light to read the complete molecular story in biological fluids seeing patterns current tests can t detect The New York Times released Saturday that it had seen investor-related materials from Haemanthus incorporated in Delaware with offices in Austin saying the startup had raised million from family and friends and that backers in the Bay Area and Texas had kicked in another million The startup intends to scan blood saliva or urine from pets and analyze the samples on a molecular level the paper informed Holmes will have no role at Haemanthus even in the future the startup asserted but noted it has learned from her company s mistakes The fallen Theranos founder stated in a court filing that she continues to work on ideas for patents Evans demanded Monday what involvement if any Holmes has with Haemanthus or its innovation referred this news organization to the company s X posts